Actuate Therapeutics warns of substantial doubt about its ability to continue as a going concern due to recurring losses and Nasdaq non-compliance.
SEC EDGAR, 2026-11-13: 10-Q — "substantial doubt"
Actuate Therapeutics warns of substantial doubt about its ability to continue as a going concern due to recurring losses and Nasdaq non-compliance.
Company: ACTUATE THERAPEUTICS, INC. (ACTU) Filed: 2026-11-13, 10-Q (Item none) Phrase: "substantial doubt" — "Based on the above matters, we have concluded that there is substantial doubt regarding the Company’s ability to continue as a going concern." What the filing says: Actuate Therapeutics reported that as of September 30, 2026, it had cash and cash equivalents of $2,101,816, a working capital deficit of $974,694, and an accumulated deficit of $168,520,734. The company has not generated any revenue and has incurred recurring operating losses since inception, including a net loss of $13,913,033 for the nine months ended September 30, 2026. Although the company raised net proceeds of $11,764,494 in an October 2026 public offering, management anticipates that its cash on hand will not be sufficient to fund operational and capital requirements for at least one year from the issuance date. Additionally, the company is out of compliance with Nasdaq's minimum market value of listed securities ($50 million) and minimum bid price ($1.00) requirements, which could lead to delisting and hinder future capital-raising efforts. Two ways it goes: A. The company raises additional capital or secures strategic partnerships to fund its clinical trials and operations. B. The company fails to obtain funding or maintain its Nasdaq listing, forcing it to delay, reduce, or terminate its product development or cease operations. Next date: none named Watch: A regulatory filing or public announcement regarding additional capital raises, a strategic partnership, or Nasdaq's compliance decision. Tags: going concern, delisting notice